ID: ALA556953

Max Phase: Preclinical

Molecular Formula: C23H26Cl2N4O4S

Molecular Weight: 489.00

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1ccc(NS(=O)(=O)c2cccc(Cl)c2C)c(O)c1CC(=O)NCc1ccc(N)nc1C.Cl

Standard InChI:  InChI=1S/C23H25ClN4O4S.ClH/c1-13-7-9-19(28-33(31,32)20-6-4-5-18(24)14(20)2)23(30)17(13)11-22(29)26-12-16-8-10-21(25)27-15(16)3;/h4-10,28,30H,11-12H2,1-3H3,(H2,25,27)(H,26,29);1H

Standard InChI Key:  SSFHJTZONAIWEM-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 489.00

Molecular Weight (Monoisotopic): 488.1285

AlogP: 3.61

#Rotatable Bonds: 7

Polar Surface Area: 134.41

Molecular Species: NEUTRAL

HBA: 6

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 6.92

CX Basic pKa: 7.54

CX LogP: 3.22

CX LogD: 3.27

Aromatic Rings: 3

Heavy Atoms: 33

QED Weighted: 0.38

Np Likeness Score: -1.34

References

1. Hanessian S, Therrien E, van Otterlo WA, Bayrakdarian M, Nilsson I, Fjellström O, Xue Y..  (2006)  Phenolic P2/P3 core motif as thrombin inhibitors--design, synthesis, and X-ray co-crystal structure.,  16  (4): [PMID:16290930] [10.1016/j.bmcl.2005.10.082]

Source

Source(1):

• Scientific Literature